Cover Image
市場調查報告書

全球液態切片市場預測

Global Liquid Biopsy Market Outlook to 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 352580
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
全球液態切片市場預測 Global Liquid Biopsy Market Outlook to 2020
出版日期: 2016年02月01日 內容資訊: 英文 90 Pages
簡介

全球液態切片 (液體切片檢查) 產業,預計到2020年末達到10億美元。

本報告提供全球液態切片市場相關調查分析,市場現況與展望,主要推動因素與課題,趨勢與發展,競爭情形等系統性資訊。

第1章 分析師的見解

第2章 調查手法

第3章 液態切片:簡介

第4章 市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 產業趨勢

第5章 全球液態切片市場預測

第6章 全球液態切片市場規模:各技術

  • CTC
  • ctDNA/cfDNA
  • 外吐小體

第7章 全球液態切片市場規模:各樣品類型

  • 血液
  • 尿

第8章 全球液態切片市場規模:各地區

  • 北美
  • 歐洲
  • 亞洲
  • 其他

第9章 開發平台分析

第10章 主要企業分析

  • Personal Genome Diagnostics
  • Guardant Health, Inc.
  • Pathway Genomics
  • NeoGenomics, Inc.
  • RainDance Technology
  • Trovagene, Inc.
  • Circulogene Theranostics
  • Biocartis
  • Cynvenio Biosystems, Inc.
  • Biocept, Inc.
  • ANGLE plc
  • MDxHealth
  • Clearbridge BioMedics Pte Ltd
  • Exosome Diagnostics, Inc.

圖表

目錄

The recent discovery of liquid biopsy technology and its wide applicability have sparked off a lot of interest among researchers along with the commercial players. Owing to the same, there are numerous clinical trials being organized all over the world in order to assess the potential of liquid biopsy in various fields such as cancer, prenatal screening and organ transplant monitoring.

As indicated by the new estimation carried out in our most recent study, the global liquid biopsy industry is expected to cross US$ 1 Billion mark by the end of 2020, as new products, especially those in the advanced stage of clinical studies or with pending approvals, might enter the market to support the development.

According to RNCOS' new research report "Global Liquid Biopsy Market Outlook to 2020", a major focus has been on the development of innovative products based on different technologies and different sample types. In this context, the study provides present and future outlooks for the two broad categories of liquid biopsy market; by technology and by sample type. The former comprises of the three marker categories that dominate liquid biopsy today: Circulating Tumor Cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (or exosomes). On the other hand, the latter includes the two major bodily fluid samples: blood and urine. According to report, blood is the most widely used sample type, and is expected to remain the largest market based on sample type in the coming years as well. The report also includes a detailed pipeline analysis of upcoming liquid biopsy products along with the sample type utilized.

Most of the current research is focused on utilizing liquid biopsy for diagnostic purposes, such as response evaluation, expression profiling, tumor diagnosis and treatment monitoring in a blood test. The flexible design of the liquid biopsy platform supports a variety of research areas, including Stem cell research, Oncology, Infectious Disease, Immunology, Endothelial Cells, and Fetal Cells.

The market has been divided into four major geographic regions - North America, Europe, Asia and Rest of the World. North America is the largest market for the liquid biopsy. This high share is attributed to relative high adoption of liquid biopsy, coupled with launch of new and advanced products in the market. The Asian market is poised to witness the highest growth owing to increasing focus of players in this region.

RNCOS, in its report, further covers how major trends and drivers, mainly therapy monitoring, increasing use of Circulating tumor DNA for cancer screening, growing interest of venture capital firms, etc. will propel the industry's growth. An analysis has also been done of a few factors limiting the growth of the industry.

After an exhaustive study of the industry, RNCOS has laid out the primary market players which are engaged in providing liquid biopsy based tools and services. These players are working over a vast variety of products, such as blood based tests, urine based tests, assays and instruments for sample extraction, amplification and purification, and constantly upgrading their portfolio to keep up with the latest developments in the field. Some of these players include NeoGenomics, Trovagene, Guardant Health, Biocept, Biocartis, and Pathway Genomics.

Overall, even though the market is in its nascent stage at the moment, it is expanding at an almost exponential rate. With new players entering the market, increase in the number of collaborations and strong support from research institutes, the liquid biopsy market is bound to witness rampant diversification and growth in the coming years.

Table of Contents

1. Analyst View

2. Research Methodology

3. Liquid Biopsy - An Introduction

4. Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 High Prevalence of Cancer
    • 4.1.2 Technological Advancements in Personalized Therapies
    • 4.1.3 Increasing Demand for Minimally-Invasive Biopsy Techniques
    • 4.1.4 Lower Cost
    • 4.1.5 Growing Interest of Venture Capital Firms
  • 4.2 Market Restraints
    • 4.2.1 A Less-Defined Regulatory Environment
    • 4.2.2 Comparatively Low Concentration of Molecular Biomarkers in Body Fluids
    • 4.2.3 Need for Proper Handling and Storage of the Samples
  • 4.3 Market Opportunities
    • 4.3.1 Exosomes Offer Great Advantages as Source Materials
    • 4.3.2 Next Generation Sequencing Offers Significant Opportunity
    • 4.3.3 Prenatal Screening & Organ Transplantation: Upcoming Applications
    • 4.3.4 Growing Researches on Cerebrospinal Fluid as Sample Source
  • 4.4 Industry Trends
    • 4.4.1 Strong Preference for ctDNA Among Various Biomarkers
    • 4.4.2 Blood: The Most Widely Used Sample

5. Global Liquid Biopsy Market Outlook to 2020

6. Global Liquid Biopsy Market Size by Technology

  • 6.1 Circulating Tumor Cells (CTCs)
  • 6.2 Circulating Tumor DNA/Cell free DNA (ctDNA/cfDNA)
  • 6.3 Exosomes

7. Global Liquid Biopsy Market Size by Sample Type

  • 7.1 Blood
  • 7.2 Urine

8. Global Liquid Biopsy Market Size by Geography

  • 8.1 North America
  • 8.2 Europe
  • 8.3 Asia
  • 8.4 Rest of the World (RoW)

9. Pipeline Analysis

10. Key Player Analysis

  • 10.1 Personal Genome Diagnostics
  • 10.2 Guardant Health, Inc.
  • 10.3 Pathway Genomics
  • 10.4 NeoGenomics, Inc.
  • 10.5 RainDance Technology
  • 10.6 Trovagene, Inc.
  • 10.7 Circulogene Theranostics
  • 10.8 Biocartis
  • 10.9 Cynvenio Biosystems, Inc.
  • 10.10 Biocept, Inc.
  • 10.11 ANGLE plc
  • 10.12 MDxHealth
  • 10.13 Clearbridge BioMedics Pte Ltd
  • 10.14 Exosome Diagnostics, Inc.

List of Figures:

  • Figure 5-1: Global - Liquid Biopsy Market (Million US$), 2015 & 2020
  • Figure 6-1: Global - Liquid Biopsy Market by Technology (%), 2015
  • Figure 6-2: Global - Liquid Biopsy Market for CTCs (Million US$), 2015 & 2020
  • Figure 6-3: Global - Liquid Biopsy Market for ctDNA (Million US$), 2015 & 2020
  • Figure 6-4: Global - Liquid Biopsy Market for Exosomes (Million US$), 2015 & 2020
  • Figure 7-1: Global - Liquid Biopsy Market by Sample Type (%), 2015
  • Figure 7-2: Global - Blood Based Liquid Biopsy Market (Million US$), 2015 & 2020
  • Figure 7-3: Global - Urine Based Liquid Biopsy Market (Million US$), 2015 &2020
  • Figure 8-1: Global - Liquid Biopsy Market by Geography (%), 2015
  • Figure 8-2: North America - Liquid Biopsy Market (Million US$), 2015 & 2020
  • Figure 8-3: Europe - Liquid Biopsy Market (Million US$), 2015 & 2020
  • Figure 8-4: Asia - Liquid Biopsy Market (Million US$), 2015 & 2020

List of Tables:

  • Table 4-1: Global - Cancer Incidence by Region (Million), 2020
  • Table 4-2: Comparison of the Analysis Capability of CTC's, cfDNA and Exosomes
  • Table 8-1: North America - Cancer Incidences by Type ('000), 2015 & 2020
  • Table 8-2: Europe - Cancer Incidences by Type ('000), 2015 & 2020
  • Table 8-3: Asia - Cancer Incidences by Type ('000), 2015 & 2020
  • Table 9-1: Pipeline Analysis for Liquid Biopsy
  • Table 10-1: Personal Genome Diagnostics - Liquid Biopsy Associated Product Line
  • Table 10-2: Guardant Health - Liquid Biopsy Associated Product Line
  • Table 10-3: Pathway Genomics - Liquid Biopsy Associated Product Line
  • Table 10-4: NeoGenomics, Inc. - Key Financials (Million US$), 2012-2014
  • Table 10-5: NeoGenomics - Liquid Biopsy Associated Product Line
  • Table 10-6: RainDance Technologies - Key Financials (Million US$), 2012-2014
  • Table 10-7: RainDance Technology - Liquid Biopsy Associated Product Line
  • Table 10-8: Trovagene - Key Financials (Million US$), 2013-2015
  • Table 10-9: Trovagene - Liquid Biopsy Associated Product Line
  • Table 10-10: Circulogene Theranostics - Liquid Biopsy Associated Product Line
  • Table 10-11: Biocartis Group NV - Key Financials (Million US$), 2012-2014
  • Table 10-12: Biocartis - Liquid Biopsy Associated Product Line
  • Table 10-13: Cynvenio Biosystems, Inc. - Liquid Biopsy Associated Product Line
  • Table 10-14: Biocept, Inc. - Key Financials (Million US$), 2012-2014
  • Table 10-15: Biocept, Inc. - Liquid Biopsy Associated Product Line
  • Table 10-16: ANGLE plc - Key Financials (Million US$), 2013-2015
  • Table 10-17: ANGLE plc - Liquid Biopsy Associated Product Line
  • Table 10-18: MDxHealth - Key Financials (Million US$), 2012-2014
  • Table 10-19: MDxHealth - Liquid Biopsy Associated Product Line
  • Table 10-20: Clearbridge BioMedics Pte Ltd - Liquid Biopsy Associated Product Line
  • Table 10-21: Exosome Diagnostics, Inc. - Liquid Biopsy Associated Product Line
Back to Top